Steering Committee
The purpose of this survey is to solicit information on the creative innovations and adaptations made by the hubs in response to the COVID-19 pandemic.
To elicit feedback from Principal Investigators, Administrators, and members of DTFs and DTF Work Groups regarding the Domain Task Force (DTF) structure.
To understand the barriers and facilitators to a career in clinical and translational science.
- Probably the biggest takeaway from the recent annual program meeting is that there simply isn’t enough time. However, we believe our goals for great presentations, lively discussions, and new collaborations were met. You, the CTSA community, and our many partners from NIH, FDA, PCORI, IDeA CTRs, and USDA delivered. I’ll use the term “wicked problems” rather than the largely discussed “big hairy
The purpose of this document is to communicate the guidelines for the various CTSA Program Groups (Enterprise Committees, Consortium Committees, Working Groups and Discussion Forums) that were established to execute the recommendations of the NCATS Advisory Council Working Group on the IOM Report on the CTSA Program. CLIC has also compiled a list of Frequently Asked Questions about the CTSA Program Groups Guidance.
Please note that this is a living document and is subject to change.DocumentLatest RevisionContact EmailCategoryGovernanceThe purpose of the Steering Committee (SC) is to enable bidirectional information and idea sharing between the CTSA Program Principal Investigators (PIs) and Administrators, and NCATS leadership regarding activities of the CTSA Program to advance clinical and translational science.
The UL1, TL1, and KL2 PIs and an Administrator are appointed by NCATS to serve up to 3 years. Terms typically begin January 1 of Year 1 and end on December 31 of Year 3.
The SC Co-Chairs lead the SC and organize meeting agendas. The SC Co-Chairs are the NCATS Director and 1 UL1 PI SC member. The UL1 PI Co-Chair is selected with input from NCATS leadership. A UL1 SC member is eligible for appointment as a Co-Chair after serving 1 year on the SC. Therefore, the selected UL1 SC Co-Chair serves a 2-year term in this capacity.
The CTSA Program SC is comprised of 20 members: 12 UL1 PIs, 1 KL2 PI, 1 TL1 PI, 1 Administrator, 1 PI of the CTSA Program Coordinating Center, 1 PI of the Trial Innovation Network (TIN), 1 PI of the CTSA Program Clinical Data to Health Coordinating Center (CD2H), the NCATS Division of Clinical Innovation (DCI) Director and the NCATS Director
With the CTSA Program Steering Committee approval, the SC Roles and Responsibilities has been updated on November 24, 2021 to reflect the following revisions:
- CTSA contact PIs and Admins are eligible to serve on the SC if their hub has at least 2 years remaining in the award cycle
- CTSA contact PIs and Admin SC member terms are 2-3 years depending on the number of years remaining in their hub award cycle
- NCATS Director will serve as an ex officio member of the SC effective Jan 1, 2022
- NCATS Director for the Division of Clinical Innovation will serve as the SC Co-Chair effective Jan 1, 2022
Please note that this is a living document and is subject to change.
Latest RevisionContact EmailCategoryGovernance